Compare2 records
2 records on the same 7 fields; 5 differ.
A rust rule marks a value that differs from most of the others. Fields carry their source quote where one exists.
| Field | NCT07765836↗ Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC | NCT07608627↗ 64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced … |
|---|---|---|
| Phasediffers | Phase 2 | Phase 1 |
| Status | Not yet recruiting | Not yet recruiting |
| Enrollmentdiffers | 40 | 15 |
| Startdiffers | January 2027 | 16 December 2026 |
| Sponsor class | Other | Other |
| Interventiondiffers | Drug: vilastobart (XTX101); Drug: RetifanlimabDrug: vilastobart (XTX101). 100mg administered once every 6 weeks (Day 1 of every 6-week cycle) by intravenous infusion (IV) over about 90-140 minutes. This wi… | Procedure: Biospecimen Collection; Drug: Copper Cu 64-DOTA-A2DM; Procedure: Positron Emission Tomography; Other: RadioconjugateProcedure: Biospecimen Collection. Undergo blood sample collection |
| Primary endpointdiffers | Objective response rate (ORR)Objective response rate (ORR). The primary endpoint is objective response rate for combination of vilastobart with retifanlimab. Response is measured using REC… | Incidence of adverse eventsIncidence of adverse events. Graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events version 6.0. Time frame: Up to 90… |
Why might these disagree?
- Phase. They are at different phases, so they answer different questions (safety and dose versus efficacy).
- Enrollment. Their sizes differ, which changes how precise any result can be.
- Start. They ran at different times, against different standards of care.
- Intervention. They test different drugs or combinations.
- Primary endpoint. They measure success differently, so their results are not directly comparable.